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Abstract: The aim of this work was to assess the impact of solvent selection on the microfluidic 
production of liposomes. To achieve this, liposomes were manufactured using small-scale and 
bench-scale microfluidics systems using three aqueous miscible solvents (methanol, ethanol or 
isopropanol, alone or in combination). Liposomes composed of different lipid compositions were 
manufactured using these different solvents and characterised to investigate the influence of 
solvents on liposome attributes. Our studies demonstrate that solvent selection is a key 
consideration during the microfluidics manufacturing process, not only when considering lipid 
solubility but also with regard to the resultant liposome critical quality attributes. In general, 
reducing the polarity of the solvent (from methanol to isopropanol) increased the liposome particle 
size without impacting liposome short-term stability or release characteristics. Furthermore, solvent 
combinations such as methanol/isopropanol mixtures can be used to modify solvent polarity and 
the resultant liposome particle size. However, the impact of solvent choice on the liposome product 
is also influenced by the liposome formulation; liposomes containing charged lipids tended to show 
more sensitivity to solvent selection and formulations containing increased concentrations of 
cholesterol or pegylated-lipids were less influenced by the choice of solvent. Indeed, incorporation 
of 14 wt% or more of pegylated-lipid was shown to negate the impact of solvent selection.  
Keywords: liposomes; microfluidics; solvents; formulation; particle size; pegylation; alcohol 
 
1. Introduction 
Liposomes are a versatile group of nanoparticles, which are approved for use in the clinic to 
improve the delivery of cancer agents, antifungal agents and vaccine adjuvants [1,2]. Currently, most 
approved liposome products contain already-approved drugs (e.g., amphotericin B, doxorubicin, 
bupivacaine, verteporfin) [3]. Recently, there has been a rise in follow-on ‘nanosimilars’ or generic 
liposome products being approved for use. Indeed, this has resulted in new recommendations for the 
naming of liposomal medicines such that the qualifier ‘liposomal’ or ‘pegylated liposomal’ should be 
added to the name. This recommendation, made jointly by the EMA’s human medicines committee 
and the Coordination Group for the mutual Recognition and Decentralised Procedures, aims to 
provide clearer distinctions between liposomal and non-liposomal formulations and hence avoid 
medication errors [4]. 
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However, despite the increase in their use, the manufacturing processes used in the production 
of liposomes remains relatively unchanged, with time-consuming, multi-stage batch production 
procedures being common. Furthermore, in many liposome research studies, small-scale methods 
are still used that do not offer realistic line-of-sight to a manufacturing process. This reduces our 
ability to translate liposome technology from bench to patient. To address this, new manufacturing 
methods are being investigated, which can offer scale-independent production. In particular, 
microfluidics is being widely investigated as a scale-independent production method (e.g., [5–7]). 
This method generally relies on the bottom up self-assembly of the liposomes by controlled mixing 
of lipids dissolved in an aqueous soluble organic solvent with an aqueous buffer [8,9]. Using this 
method, we have demonstrated the ability to entrap small molecules [10,11], nucleic acids [12] and 
proteins [13,14] within liposomes. We have also demonstrated the scale-independent production of 
liposomal adjuvants using this method [15–18]. 
When adopting microfluidics as a production method for liposomes, the lipids are dissolved in 
an organic solvent (normally alcohol), which is then mixed with the aqueous phase to promote 
nanoprecipitation and liposome production. Therefore, the solvent selected must dissolve the lipid 
component and be water soluble. The water miscibility of organic solvents is directly related to 
carbon chain length and surface tension as shown in Figure 1 (adapted from [19]). As the length of 
the carbon chain increases, the polar OH group becomes a smaller component of the solvent 
molecule. The solubility and the polarity of alcohol decreases correspondingly. The solubility of 
organic solvents in water is also driven by hydrogen-bonding interactions between water and 
solvent. For example, water and short-chain solvents such as ethanol are completely miscible due to 
the ability of the ethanol molecules to form hydrogen bonds with water molecules as well as with 
each other [20]. However, when considering solvent selection for use in microfluidics, lipid solubility 
and water miscibility are not the only factors. Whilst in the purification process solvent is removed, 
working with solvents that have low toxicity potential and defined as Class 3 in the ICH Q3C (R6) 
[21] (e.g., ethanol and isopropanol (IPA)) is preferable followed by those in Class 2 (e.g., methanol) 
(Figure 1). 
 
Figure 1. The relationship between aqueous solubility and the number of carbon atoms in alcohols 
determined by surface tension (adapted from [19]) and physical properties of methanol, ethanol, and 
isopropanol. 
Typically, IPA has been used as the lipid solvent in microfluidic processes [8,22–24], with fewer 
studies exploring other solvents such as ethanol as a less toxic alternative for medicinal applications, 
which would also comply with routine industrial processes [25]. However, the choice of solvent used 
during microfluidics may have an impact; Zook and Vreeland hypothesised that liposomes formed 
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due to the alcohol and aqueous phase mixing, increasing the polarity of the solvent, which caused 
the lipids to become progressively less soluble and self-assemble into planar lipid bilayers [26]. The 
authors noted that as the planar bilayers increase in size, to reduce the surface area of hydrophobic 
chains exposed to the polar solvent around the edge of the discs, they bend and form spherical 
liposomes (Figure 2) [12]. Given that this change in polarity will be dependent on the initial polarity 
of the alcohol selected, solvent polarity is a critical material attribute to consider as it will impact both 
on initial lipid solubility but also on the nanoprecipitation process. Therefore, the aim of this work 
was to evaluate the impact of solvent selection on the formulation of liposomes in terms of their 
physicochemical parameters, such as particle size, polydispersity index, liposome stability and 
drug/protein loading. To achieve this, we initially employed a low volume high throughput 
microfluidic system as a screening process, followed by more detailed formulation studies using 
larger volume microfluidic systems.  
 
Figure 2. A hypothesised liposome formation mechanism (adapted from Zook and Vreeland [26]). 
The process starts with the aggregation of lipids in discs (a). It is proposed that the hydrophobic chains 
around the edges are stabilised by alcohol molecules. As the alcohol concentration reduces these lipid 
discs bend (b), rapidly close (c), and form liposomes (d). 
2. Materials and Methods  
2.1. Materials 
Soy bean phosphatidylcholine (SoyPC), hydrogenated soy phosphatidylcholine (HSPC), 1,2-
distearoyl-sn-glycero-3-phosphocholine (DSPC), 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-
N-[methoxy(polyethylene glycol)-2000] (DSPE-PEG2k) were obtained from Lipoid (Ludwigshafen, 
Germany). 1,2-dimyristoyl-sn-glycero-3-phospho-(1′-rac-glycerol) (DMPG), 1,2-dioleoyl-sn-glycero-
3-phosphoethanolamine (DOPE), 1,2-dimyristoyl-sn-glycero-3-phosphocholine (DMPC), 1-
palmitoyl-2-oleoyl-glycero-3-phosphocholine (POPC), 1,2-dioleoyl-3-trimethylammonium-propane 
(chloride salt) (DOTAP) were purchased from Avanti polar lipids, Alabaster, AL, USA. Cholesterol 
(Chol), chicken egg ovalbumin (OVA), and propofol were acquired from Sigma-Aldrich (St. Louis, 
MO, USA). Phosphate buffered saline was acquired from Oxoid Ltd, Basingstoke, UK. Tris-base was 
obtained from IDN Biomedical Inc. (Aurora, OH, USA). Methanol (MeOH), ethanol (EtOH) and 
isopropanol (IPA) were obtained from Fisher Scientific, Loughborough, UK. All solvents and other 
chemicals were used at analytical grade, and mQ-water was provided by an in-house system. 
2.2. Microfluidic Production of Liposomes 
2.2.1. Initial Rapid Small-Scale Screening Studies 
The liposomes were prepared with a phospholipid:cholesterol ratio of 3:1 (SoyPC and POPC) or 
2:1 (HSPC, DMPC and DSPC) weight ratio. Pegylated liposomes (DSPC:Chol:DSPE-PEG2k) were 
prepared at a 2:1:1 w/w. Anionic liposomes were prepared from DMPC:Chol:DMPG or 
DSPC:Chol:DMPG at 10:5:4 w/w and cationic liposomes were prepared from DOPE:DOTAP at 1:1 
w/w, HSPC:Chol:DOTAP at 1:2:4 w/w and HSPC:Chol:DOTAP:DSPE-PEG2k at 1:2:4:0.5 w/w. These 
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formulations were selected to represent commonly reported formulations. For microfluidic 
production, the lipids were dissolved in methanol, ethanol or isopropanol at 4 mg/mL. For initial 
rapid screening, the formulations were prepared using a SparkTM (Precision Nanosystems Inc., 
Vancouver, Canada). Disposable microfluidic chips were loaded with 31 µL lipid stock and 93 µL 
PBS or Tris buffer in the reaction chambers, respectively. The receiving chamber was filled with 124 
µL PBS or Tris buffer (pH 7.4, 10 mM). With formulations prepared with OVA, the protein was added 
to the PBS at a concentration of 1 mg/mL, whilst for formulations with propofol, the drug was added 
to the lipid stock solution at 1 mg/mL. The formulations were processed at setting 8–10, and the 
product transferred to a glass vial and further diluted with 1000 µL PBS or deionised water. All 
formulations were prepared at room temperature. 
2.2.2. Preparation of Liposomes Using a Bench-Scale System 
Liposomes were prepared with DSPC:Chol (2:1 to 8:1 w/w ratio; 11 to 33% cholesterol content) 
and DOPE:DOTAP (1:1 w/w ratio) and 4 mg/mL initial lipid concentration by using a NanoassemblrTM 
(Precision Nanosystems Inc.). Increasing levels of DSPE-PEG2k (0 to 25 wt%) were also tested with 
the DSPC:Chol formulation. A range of alcohol mixtures were tested as the organic phases: 
methanol/ethanol, methanol/IPA and ethanol/IPA at combinations of 100/0, 75/25, 50/50, 25/75 and 
0/100 v/v%. Tris-buffer (10 mM, pH 7.4) was used as the aqueous phase at a flow rate ratio of 1:1 for 
the DOPE:DOTAP. For DSPC:Chol formulations, PBS at a flow rate ratio of 3:1 was used. Again, all 
formulations were prepared at room temperature. 
2.3. Characterization of Particle Size, Polydispersity and Zeta Potential by Using Dynamic Light Scattering 
The particle sizes, measured as the hydrodynamic diameters, polydispersity indexes (PDI) and 
zeta potentials were measured by dynamic light scattering using a Zetasizer Nano ZS (Malvern 
Instruments Ltd, Worcestershire, UK) equipped with a 633 nm laser and a detection angle of 173°. 
The samples were measured and the values of water were used for refractive indexes and viscosity. 
Zetasizer Software v.7.11 (Malvern Instruments Ltd.) was used for the acquisition of data. 
2.4. Removal of Free Drug with Tangential Flow Filtration (TFF) 
The OVA and propofol in the drug loaded samples were removed by tangential flow filtration 
by using a Krosflo KR2i TFF system (Waltham, MA, USA) equipped with an mPES 300 kD or 750 kD 
column. The sample volume was 1 mL and the purification process was repeated 12 times. All 
samples were recovered at the initial volume. 
2.5. Characterisation of Drug Loading 
OVA (43 kDa) and propofol (178 Da) were selected as a water soluble and bilayer soluble drug 
respectively to consider drug loading. These were selected as we previously investigated drug 
loading via microfluidics using these two moieties [11,13]. The content of propofol in propofol-loaded 
formulations after purification with TFF was determined using HPLC as described in [27]. Propofol 
loading was calculated as the percent of propofol in the liposome formulation after TFF purification 
to the initial concentration in the untreated sample. The content of OVA in the OVA loaded samples 
after purification with TFF was quantified using either the bicinchoninic acid assay (BCA) (Thermo 
Fisher Scientific, Waltham, MA, USA) or via HPLC using a modified published method [28]. A Jupiter 
5 µm C5 300A column 4.6 mm i.d. × 250 mm length (Phenomenex, Macclesfield, UK) was used with 
a gradient flow (0.1% TFA in water (A), 0.1% TFA in acetonitrile (B)). A UV detector was fitted at 210 
nm for all OVA loaded samples (retention time 10.6–14 mins) whilst 280 nm was used for the protein 
release study (retention time 8–14 mins).  
2.6. Morphological Characterisation of Liposomes via CryoTEM 
Samples were prepared by placing 5 µL of liposomes onto a 400-mesh lacey carbon-coated grid 
using single sided blotting for 2 s then immediately immersing the sample grid into nitrogen cooled 
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ethane (100% ethane). The liposome morphology was then observed using the Joel Jem F-200 
microscope (Joel, Tokyo, Japan) at liquid nitrogen temperature and 200 kV. 
2.7. Liposome Stability Studies 
Neutral liposomes (DSPC:Chol 2:1 w/w) were produced using microfluidics at a 3:1 FRR and 15 
mL/min TFR (4 mg/mL initial lipid concentration) in either MeOH, EtOH or IPA. Solvent was 
removed by TFF (12 mL wash cycle per mL of sample). Liposome suspensions were then stored at 2–
8 °C in the fridge and their size and PDI was measured over 7 days with the Zetasizer Nano ZS 
(Malvern Instruments Ltd, Worcestershire, UK) using a 1/10 dilution with purified water. 
2.8. Drug Release Studies 
Ovalbumin loaded entrapped within DSPC:Chol liposomes were produced using microfluidics 
at a 3:1 FRR and 15 mL/min TFR (16 mg/mL initial lipid and 1 mg/mL initial Ovalbumin) using 
MeOH, EtOH or IPA. These formulations were then purified via TFF as previously described. 1 mL 
of purified formulation was added into a 300 kD float-a-lyzer™ (Spectrum™, Breda, The 
Netherlands) in the presence of 20 mL PBS (pH 7.4 ± 0.2). The samples were incubated at 37 °C with 
agitation and at 0, 24, 48 and 72 h 100 µL of the sample was removed and protein retention was 
quantified using the described RP-HPLC method. 
3. Results 
3.1. Rapid Pre-Screening of Liposome Manufacture Indicates that Liposome Size can be Influenced by Solvent 
Selection 
To investigate the impact of solvent selection during microfluidic production on the properties 
of liposomes, we initially screened a panel of liposome formulations using a small-volume high-
throughput microfluidic system (SparkTM; Precision Nanosystems Inc.). Initially a panel of six 
liposome formulations were tested, which contained a combination of a phosphatidylcholine and 
cholesterol, and in one formulation we also incorporated a PEG-coating (Figure 3). The results 
showed that the solvent selected could have an impact on liposome size depending on the 
formulation. In general, the SoyPC and POPC liposome formulations (PC:Chol 3:1 w/w) tended to 
show a greater impact from the solvent adopted in terms of particle size. For example, with both 
formulations the liposome particle size approximately doubled when liposomes were formulated 
using IPA compared to methanol. With the SoyPC:Chol formulation, liposomes increased in size 
from 70 to 135 nm as we moved from methanol to IPA (Figure 3A) and the POPC:Chol liposomes 
increased from 81 to 161 nm (Figure 3B). When the liposomes were prepared from DMPC, DSPC and 
HSPC (2:1 w/w with cholesterol; Figure 3C, D and E respectively), there was less impact on particle 
size as we decreased the solvent polarity. For example, DMPC:Chol liposomes increased in size from 
149 to 190 nm as we switched from methanol to IPA (Figure 3C), DSPC:Chol increased from 83 to 104 
nm (Figure 3D) and HSPC:Chol liposomes increased from 88 to 122 nm (Figure 3E). Across all these 
formulations, the general trend of increasing liposome size in terms of IPA > ethanol > methanol 
could be seen with the exception of the pegylated formulation. When DSPE-PEG2k was included in 
the formulation (DSPC:Chol:PEG2k) the liposomes were similar in size (approximately 60 nm) 
irrespective of the solvent used in their manufacture (Figure 3F). Across all formulations, the PDI was 
in the range of 0.2 to 0.4, with no impact from the solvent used (Figure 3).  
To further explore the impact of solvent selection, we also tested a selection of anionic (Figure 4) 
and cationic (Figure 5) formulations. In terms of the anionic formulations (DMPC:Chol:DMPG and 
DSPC:Chol:DMPG), again we saw the general trend of increasing particle size (from approximately 
100 to 160 nm) for both the DMPC and DSPC formulations (Figure 4A and B respectively) as we 
progressed from methanol to IPA. Again, for all formulations the PDI remained in the range of 0.2 to 
0.4 (Figure 4). The impact of solvent selection on the zeta potential was also tested; no significant 
difference was seen across the anionic liposome formulations irrespective of the solvent selected for 
their production (−15 to −25 mV; Figure 4C and D).  
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Figure 3. Initial low-volume, high-throughput screening of liposomes formulated using different 
solvents during microfluidic production. Liposomes were prepared using a low volume, high 
throughput screening system (SparkTM). Different water miscible organic solvents (methanol, ethanol 
or IPA) were used in combination with the aqueous phase. A flow rate ratio of 3:1 aqueous:organic 
phase was used with 4 mg/mL total lipid concentration in the organic phase. Various liposome 
formulations were tested: (A) soyPC:Chol 3:1 w/w, (B) POPC:Chol 3:1 w/w, (C) DMPC:Chol 2:1 w/w, 
(D) DSPC:Chol 2:1 w/w, (E) HSPC:Chol 2:1 w/w, (F) DSPC:Chol:DSPE-PEG2k 2:1:1 w/w. Columns 
represent particle size and open circles represent PDI. Results represent mean ± SD from three 
independent batches. 
 
Figure 4. The effect of solvent selection on the particle size of anionic liposomes. Liposomes were 
prepared using different water miscible organic solvents (methanol, ethanol or IPA) and PBS as 
aqueous phase on the SparkTM microfluidic system as shown in Figure 3. A flow rate ratio of 3:1 
aqueous:organic phase was used with 4 mg/mL total lipid concentration in the organic phase. Particle 
size and PDI (columns and open circles, respectively) are shown for (A) DMPC:Chol:DMPG 10:5:4 
w/w, and (B) DSPC:Chol:DMPG 10:5:4 w/w formulations. The zeta potential for (C) 
DMPC:Chol:DMPG 10:5:4 w/w, and (D) DSPC:Chol:DMPG 10:5:4 w/w is also shown. Results represent 
mean ± SD from three independent batches. 
With the cationic (DOPE:DOTAP) formulations, again we see a trend of increasing liposome size 
as we decrease the polarity of the solvent, with sizes increasing from approximately 50 nm, to 100 nm 
to 150 nm when formulated in methanol, ethanol and IPA respectively (Figure 5A). When the 
HSPC:Chol:DOTAP formulation was made in methanol or ethanol, particle size increased from 120 
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nm to 230 nm, respectively (Figure 5B). With this formulation, IPA could not be tested due to 
precipitation of the formulation. Interestingly, when PEG was added into this formulation, 
precipitation was not an issue and the solvent adopted in the microfluidic process had no impact on 
particle size (76–96 nm irrespective of the solvent used; Figure 5C) and the PDI remained in the range 
of 0.2 to 0.4. As with the anionic formulations, the zeta potential of the formulations were not 
influenced by the solvent selected with DOPE:DOTAP and HSPC:Chol:DOTAP formulations being 
in the range of 50 to 60 mV (Figure 5D and E) and the pegylated cationic formulation being 20–30 mV 
(Figure 5F).  
 
Figure 5. The effect of solvent selection on the particle size of cationic liposomes. Liposomes were 
manufactured as outlined in Figure 3. A flow rate ratio of 3:1 aqueous:organic phase was used with 4 
mg/mL total lipid concentration in the organic phase and Tris buffer (10 mM, pH 7.4) as the aqueous 
phase. Particle size and PDI (columns and open circles, respectively) for (A) DOPE:DOTAP 1:1 w/w, 
(B) HSPC:Chol:DOTAP 1:2:4 w/w and (C) HSPC:Chol:DOTAP:DSPE-PEG2k 1:2:4:0.5 w/w. The zeta 
potential for these three formulations are shown in (D), (E) and (F) respectively. Results represent 
mean ± SD from three independent batches. 
The applicability of using this low volume microfluidic system (SparkTM) as a high-throughput 
screening tool for liposome formulations was also tested in terms of drug loading. Figure 6 
demonstrates that even with low volume formulation testing (down to 100–250 uL) drug loaded 
liposomes can be prepared rapidly for initial screening with drug loading of low soluble drugs 
(propofol) and large biologicals (OVA) being achieved at levels comparable (40% for propofol [13] 
and 25–30% for OVA [28]) to those previously reported with the larger bench-top microfluidic 
systems. 
 
Figure 6. Liposome loading efficiencies for the (A) bilayer loaded drug (propofol, 1 mg/mL in MeOH) 
and (B) aqueous core loaded drug (OVA, 1 mg/mL in PBS) produced using rapid through-put 
microfluidics (SparkTM). Liposomes were prepared with soyPC:Chol and HSPC:Chol, 3:1 w/w, 10 
mg/mL in MeOH. Results represent mean ± SD from three independent batches. 
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3.2. The Impact of the Solvent is Dependent on the Liposome Formulation 
To further consider the impact of the liposome formulation in combination with solvent 
selection, DSPC:Chol liposome formulations were prepared with varying cholesterol content from 11 
to 33 wt% and the bench-top NanoAssemblrTM was employed. As this system was designed for the 
formulation and development of nanomedicines, it offered the ability for liposomes to be collected 
during the steady state microfluidic production and hence produced homogeneous suspensions with 
PDI commonly below 0.2. Figure 7A shows that as we increased the cholesterol content, the liposome 
size reduced with all three solvents. The results also showed the trend of liposome size increased as 
we progressed from methanol, to ethanol, to IPA irrespective of the cholesterol content used. 
However, at higher cholesterol concentrations the difference in size between the liposomes formed 
in the different solvents was reduced (Figure 7A). Furthermore, at low cholesterol concentrations (11 
wt%) liposomes could only be manufactured using methanol (Figure 7A). Attempts to manufacture 
this liposome formulation with ethanol or IPA resulted in large aggregates forming.  
The addition of PEG-lipid to the DSPC:Chol (2:1 w/w; 33 wt% cholesterol) was then investigated 
with ethanol and IPA (Figure 7B). At low PEG lipid content (8%), we saw that the choice of solvent 
significantly (p < 0.05) impacted particle size (60 vs. 90 nm for ethanol and IPA respectively; Figure 
7B). However, as we increased the PEG-lipid content to 14% or more, we saw the effect of solvent 
was negated (Figure 7B). 
 
Figure 7. The effect of increasing cholesterol content and PEG-lipid in liposomes manufactured using 
microfluidics and different solvents. (A) Cholesterol was increased from 11 to 33 wt% in DSPC:Chol 
liposomes and (B) PEG-lipid content was increased from 0 to 25% within DSPC:Chol:PEG2k 
liposomes. Liposomes were prepared at a FRR of 3:1 and TFR of 15 mL/min for DSPC:Chol liposomes 
and 12 mL/min for DSPC:Chol:DSPE-PEG2k liposomes. Initial lipid concentration for both 
formulations was 4 mg/mL. Results represent mean ± SD from three independent batches. 
3.3. Varying the Solvent Mixture Composition Impacts on Liposome Particle Size 
To further study the link between solvent selection and particle size, Figure 8 explores in detail 
the impact of solvent mixtures on the particle size attributes of liposomes formulated from 
DSPC:Chol. From Figure 8A, we can see that as we increased the ethanol content within the 
methanol/ethanol solvent mix from 0 to 100%, the particle size increased only moderately from 45 to 
55 nm with the PDI remaining below 0.2 and the suspensions were unimodal in nature (Figure 8B). 
When we consider the impact of IPA on the formulations, the increase in size was more notable. 
DSPC:Chol liposomes prepared using mixtures of methanol/IPA showed an increase in size from 45 
nm up to 93 nm as we increased the IPA content from 0 to 100% (Figure 8C), again with the PDI 
remaining below 0.2 and the particle size being unimodal (Figure 8D). When these liposomes were 
prepared using mixtures of ethanol/IPA, we could similarly see an increase in size (from 55 to 93 nm 
as we go from 0 to 100% IPA; Figure 8E). Again, the PDI of all formulations remained <0.2 and were 
unimodal in nature (Figure 8F). These results show that we can control the liposome particle size via 
controlling the solvent mixture.  
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To test if similar size control could be achieved with cationic formulations, again a range of 
methanol/ethanol solvent mixtures were tested (Figure 9). Once, again the particle size was controlled 
through the polarity of the solvent mixture. By increasing the ratio of ethanol, the liposome size 
increased from 33 to 58 nm (Figure 9A) with the PDI remaining below 0.2 and the formulations being 
unimodal in nature (Figure 9B and C). Again formulating these formulations with IPA increased the 
size (up to 120 nm; Figure 9A) but did increase the polydispersity of the formulation (Figure 9B and 
C). However, across all the formulations, the cationic zeta potential remained high (40–60 mV; Figure 
9D). 
 
Figure 8. Investigating the effect of solvent mixtures on physical liposome characteristics. Particle size 
and PDI recorded with lipids dissolved in (A) Methanol:Ethanol mix 0–100%, (C) 
Methanol:Isopropanol mix 0–100%, (E) Ethanol:Isopropanol mix 0–100% with intensity plots for each 
respective solvent mix shown in (B), (D) and (F). Liposomes were composed of DSPC:Chol (2:1 w/w), 
which were produced using a FRR of 3:1; 15 mL/min TFR and initial lipid concentration of 4 mg/mL. 
Results represent mean ± SD from three independent batches. 
 
Figure 9. Controlling the vesicle size of cationic liposomes using solvent mixtures. DOPE:DOTAP (1:1 
w/w) liposomal formulations were prepared using the NanoAssemblrTM bench-scale system. A flow 
rate ratio of 1:1 aqueous:organic phase was used with 4 mg/mL total lipid concentration in the organic 
phase and Tris buffer (10 mM, pH 7.4) as aqueous phase. Solvent mixtures of methanol/ethanol and 
IPA were tested. Results are shown as (A) Particle size, (B) PDI, (C) Intensity plots and (D) Zeta 
potential of the formulations. Results represent mean ± SD from three independent batches. 
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3.4. Solvent Choice Influences Liposome Morphology and Initial Protein Loading but does not Impact 
Liposome Stability nor Release Attributes 
To further investigate the impact of solvent choice during microfluidic manufacturing, 
DSPC:Chol (2:1 w/w) were prepared incorporating protein (OVA) (Figure 10). From the results in 
Figure 10A, we can see that there was no significant difference in protein loading for liposomes 
prepared with methanol and ethanol (35–40%; Figure 10A), but protein loading was significantly (p 
< 0.05) reduced when IPA (20%; Figure 10A) was used for the manufacturing process. Interestingly, 
when considering the morphology (Figure 10B), we can see that liposomes formed as small 
unilamellar vesicles when prepared using methanol or ethanol, whilst those formed with IPA were 
larger and had one or two bilayers. In terms of stability, all three liposome formulations showed good 
short-term stability when stored at 2–8 °C (Figure 10C) with no significant difference in size being 
noted over the length of the study. Similarly, there was no significant difference in protein release 
profiles of the liposomes prepared using methanol, ethanol or IPA with approximately 80% protein 
release after 72 h (Figure 10D). 
  
  
Figure 10. Solvent selection and its impact on OVA encapsulation, morphology, liposome stability 
and protein release. (A) Protein entrapment efficiency of liposomes loaded with 0.25 mg/mL OVA 
with an initial lipid concentration of 4 mg/mL produced using methanol, ethanol or isopropanol. (B) 
the morphology of liposomes obtained by cryoTEM in the respective solvents. (C) Stability of ‘empty’ 
liposomes stored at 2–8 °C over 7 days at an initial lipid concentration of 4 mg/mL. (D) Protein release 
profiles of liposomes (initial concentration of 16 mg/mL loaded with 1 mg/mL OVA) was investigated 
over 72 h at 37 °C to access if solvent selection impacted membrane permeability. Liposomes were 
composed of DSPC:Chol (2:1 w/w) and produced at a 3:1 FRR and 15 mL/min. Results represent mean 
± SD from three independent batches. 
4. Discussion 
Microfluidic production offers new manufacturing strategies for the production of liposomes 
and other nanoparticles. This method can be scale-independent [16,29] and thus gives formulation 
scientists a direct route to translate their research off the bench into the clinic. When considering 
liposomes, there are a range of parameters that are critical quality attributes. Amongst these, vesicle 
size is particularly important given its impact on biodistribution, which is a key feature in the ability 
of liposomes to improve drug delivery, enhance efficacy and reduce off target toxicity. It is widely 
reported that critical process parameters that influence the size of nanoparticles produced via 
microfluidics include the micromixer design (e.g., [30]) and the rate of mixing (e.g., [13,16,17,31]). 
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Within this study, we demonstrated that solvent selection was also a critical process parameter in the 
manufacture of liposomes using microfluidics as it could impact on particle size. Furthermore, we 
demonstrated that alcohol mixtures could be used to manipulate liposome size. However, the 
sensitivity of the liposome particle size to solvent selection was dependent on the given liposome 
formulation. This can be tested using rapid low volume screening protocols (as outlined in Figures 
3–6), which is particularly useful in early studies where lipids and active pharmaceutical ingredients 
may be limited. However, changes in particle size when switching between methanol and ethanol 
were generally low (Figures 7–9). When produced by microfluidics, liposome sizes tended to increase 
with decreased solvent polarity across all the formulations tested and size control of the liposomes 
could be achieved using solvent mixtures (Figures 8 and 9). Furthermore, increasing concentrations 
of cholesterol or pegylated-lipid formulations tended to reduce the impact of the solvent selections, 
and formulations containing over 14% PEG-lipid did not show a notable sensitivity to the alcohol 
used in their manufacture (Figure 7). Despite differences in morphology, the liposomes formulated 
using methanol, ethanol or IPA all showed good stability and similar protein release profiles (Figure 
10). 
A range of models have been proposed for the self-assembly of liposomes due to the mixing of 
water miscible solvents and recently Zook and Vreeland proposed a non-equilibrium model [26]. 
Their model proposed that liposome size was determined by two factors: 1) the growth rate of planar 
bilayer discs and 2) the rate the discs close into spherical vesicles (Figure 2). In their studies, Zook 
and Vreeland [26] tended to focus their investigations on considering the impact of the rate of disc 
closure, and the authors showed that the radius of the liposomes formed during their microfluidic 
process was proportional to the ratio of membrane bending elasticity modulus to the hydrophobic 
edges of the lipid discs formed. In general, the membrane elasticity modulus of a bilayer is higher 
with longer alkyl chain length/high transition temperature lipids (i.e., DSPC > DPPC > DMPC in 
terms of bending elastic modulus, and a higher elastic modulus indicates a more rigid membrane). 
Therefore, bilayer discs formed during the microfluidic process (as shown in Figure 2A) should be 
more rigid and less able to bend when the membrane is at or below the bilayer transition temperature 
[26]. Thus, at room temperature high transition temperature bilayer formulations would form larger 
liposomes. Indeed, in discussing their model, Zook and Vreeland note that temperature is a key 
consideration and increasing the temperature above the lipid transition temperature will increase 
elasticity and hence reduce particle size [26]. These findings were not in line with the results shown 
in Figure 3 (e.g., DMPC vs. DSPC formulations) nor with our previous findings [13]; we show that 
increasing the carbon chain length of the PC lipid results in smaller liposomes being formed. 
Similarly, we have previously shown that during the microfluidic production, liposomes produced 
at room temperatures or at a temperature above the main lipid transition temperature were similar 
in size; we were able to prepare DSPC:Chol liposomes of the same size at production temperatures 
from 20 to 60 °C. This demonstrates that there was no requirement to work above the lipid transition 
temperature during the microfluidic manufacturing process [13]. Therefore, in our studies, the impact 
of temperature on membrane elasticity is not a key contributing factor controlling liposome size. 
However, it can be useful to use elevated temperatures to improve the solubility of some lipids in 
solvents during the processes irrespective of their Tc (e.g., [16]). 
When considering bilayer rigidity, cholesterol content is also a key factor as the transition 
temperature of liposome bilayers (Tc) varies when mixtures of different hydrocarbon chain length 
phospholipids are compared to pure lipids [32]. In the absence of cholesterol, the hydrocarbon chains 
of the lipids in the bilayer crystallize into the rigid-crystalline phase which results in, for example, 
the Tc for DSPC liposomes being 55 °C [32]. However, with the addition of 33 mol% cholesterol, this 
transition temperature is no longer detectable [33]. Similarly, the large head-group component of 
charged lipids or pegylated lipids can reduce/negate the transition temperature of lipid bilayers by 
inhibiting the packaging of the lipids into the rigid-crystalline phase. Moreover, it has also been 
shown that adding cholesterol to liposome bilayers tends to increase the elasticity of the membrane 
[34,35]. From Figure 7, we can see that increasing the cholesterol content within liposomes resulted 
in reduced vesicle sizes, and this may be attributed to the increased elasticity and more rapid closure 
Pharmaceutics 2019, 11, 653 12 of 15 
 
of the discs into smaller liposomes. The presence of higher levels of cholesterol and PEG-lipid was 
also shown to negate the effect of solvent selection on particle size. This suggests that the geometric 
packaging of these lipids within a bilayer and subsequently into a liposome may overrule the impact 
of solvent choice. 
Alcohols are known modulators of bilayer properties and this may explain why temperature 
and lipid bilayer transition temperature are not factors in our process. Whilst the alcohol is removed 
from the liposome formulations after production (via tangential flow filtration within our studies), 
during the microfluidic mixing phase this is a consideration. There are various studies which 
demonstrate the ability of alcohols to change the lipid bilayer free volume and promote bilayer 
disorder, and it has been reported that the bilayer-modifying potency of short-chain alcohols scales 
linearly with their bilayer partitioning [36]. Within a bilayer, alcohols have their –OH group in the 
bilayer interfacial region and their hydrophobic methyl groups in the hydrophobic core of the bilayer 
and thus they disrupt the bilayer packing [37]. Thus, the impact of the alcohol on the bilayer will 
depend both on the alcohol and the composition of the bilayer [36]. Indeed, the ability of ethanol to 
enhance the bilayer permeability has been exploited to improve pH gradient loading of cholesterol-
free liposomes [38]. Normally, for pH gradient loading, the liposomes are incubated at temperatures 
above their phase transition temperature to promote drug loading. However, in cholesterol free 
bilayers, increased temperatures can result in the collapse of the pH gradient. Therefore, Dos Santos 
et al. [38] circumvented this problem by the addition of ethanol as a permeability enhancer. Ethanol 
is also reported to reduce the transition temperature of lipid bilayers (through promoting bilayer 
disorder) and at high concentrations can cause lipid interdigitation [39,40]. This disordering effect is 
not restricted to ethanol, and all three of the alcohols used within our studies had a bilayer 
disordering effect [41]. Thus, during the production of liposomes, the miscible alcohols present 
during the mixing process may reduce the transition temperature of the bilayer discs, hence 
increasing their elasticity and promoting vesicle formation. Yet, given that the release properties of 
the three different liposome formulations were similar (Figure 10), this suggested that on purification 
of the liposomes via TFF, the residual solvent was removed (as shown previously [13]) and there was 
no difference in fluidity/permeability of the different liposome products.  
Given that in our process the membrane elasticity and rate of membrane closure (Figure 2C and 
D) did not appear to be a key factor, the link between solvent selection and liposome particle size 
may be linked to the process outlined in Figure 2a and the initial size of the lipid discs formed [26]. 
During the mixing process of the alcohol and buffer, an increase in the polarity results in the 
formation of the discs. As we reduce the polarity of the alcohol used (going from methanol to IPA), 
the rate of change in polarity during the mixing process will be reduced. This may result in larger 
discs being formed, which subsequently close into larger liposomes. Higher concentrations of 
cholesterol or PEG-lipids may inhibit the packaging of lipids into larger discs. The longer chain IPA 
may also provide additional stabilization for the lipid discs formed, which could also contribute to 
the formation of larger liposomes, as suggested by Zook and Vreeland [26]. However, within their 
studies only IPA was used and therefore the impact of solvent selection on this stabilizing effect was 
not clear. 
5. Conclusions 
From our studies, we demonstrate that solvent selection is a key consideration in developing a 
microfluidic manufacturing process for liposome production. In terms of solvent selection, ethanol 
offers a range of advantages including its suitability for large scale manufacture and its Class 3 status. 
However, a range of solvents can be considered (e.g., octanol [42], IPA [8], methanol [30]) and solvent 
selection can be used to control liposome size. Furthermore, upon appropriate dilution/solvent 
removal the efficacy of the produced liposomes can be equivalent (e.g., [43]). Within our current 
studies, we outline a rapid high-throughput method for initially screening the impact of solvent 
selection on liposome attributes. We also show that alcohol mixtures can be used to fine-tune the 
liposome size. We have previously shown that buffer concentration can be used to offer size control 
[18]. Therefore, liposome size is under the influence of alcohol and the salt concentration of the 
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aqueous buffer and both are key process parameters that should be considered in the development 
of microfluidic manufacturing processes.  
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